Loading...

CPRX CATALYST PHARMACEUTICALS INC Product Launches 8-K Filing

CTLY

CPRX

CATALYST PHARMACEUTICALS INC

(CPRX)

2025 8-K

Show Summary

Summary

Patent Settlement Update

Patent Litigation Settlement

Financial Statements

Financial Statements

Drug Submission Update

Earnings Announcement

Director Departure

Corporate Presentation

Patent Settlement

Earnings Announcement

License Agreement with Kye ...

Annual Meeting Results

Earnings Reports

Earnings Reports

Publication of Study on Vam...

Public Offering

Corporate Presentation

Public Offering

Collaboration Partner NDA S...

CFO Retirement and Appointment

Earnings Reports

Patent Allowance

FDA Approval for AGAMREE

Appointment of CEO

FDA Acceptance of Supplemen...

Participation in Cantor Glo...

Earnings Reports

Retirement of CEO

Asset Acquisitions

License and Collaboration A...

Appointment of New Director

Earnings Report

FDA Meeting for FIRDAPSE Do...

Departure of Directors

Earnings Reports

Completion of Acquisition o...

Notice Letter from Teva Pha...

External Links:

On April 8, 2025, Catalyst Pharmaceuticals announced that Health Canada accepted the New Drug Submission for AGAMREE, a potential treatment for Duchenne Muscular Dystrophy, with a Priority Review status that could lead to marketing approval by the end of 2025.

AI Assistant

CATALYST PHARMACEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.